v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Current Assets    
Cash $ 180 $ 14,774
Total Current Assets 180 14,774
Operating lease right-of-use asset 3,630 4,272
Security deposit 1,995 1,995
TOTAL ASSETS 5,805 21,041
Current Liabilities    
Accounts payable and accrued liabilities 1,189,520 1,084,763
Shareholders’ notes payable 49,000 49,000
Operating lease liability – current portion 2,860 2,860
Accrued interest payable 20,239 19,279
Total Current Liabilities 2,560,679 2,319,968
Operating lease liability – long term portion 3,210 3,684
Total liabilities 2,563,889 2,323,652
Stockholder’s Deficit:    
Preferred stock, $0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 80,000,000 shares authorized; 18,754,739 shares issued and outstanding at March 31, 2026 and December 31, 2025 1,875 1,875
Additional paid-in capital 15,889,147 15,679,131
Stock subscription receivable (125,000)
Accumulated deficit (18,449,106) (17,858,617)
Total Stockholders’ Deficit (2,558,084) (2,302,611)
TOTAL LIABILITIES AND STOCKHOLDER’S DEFICIT 5,805 21,041
Sanovas Ophthalmology LLC [Member]    
Current Liabilities    
Due to related parties 830,632 674,842
Related Party [Member]    
Current Liabilities    
Due to related parties $ 468,428 $ 489,224